A science administrator is allocating $2.4 million in research grants across three phases of a gene therapy project. Phase 1 receives 25% of the total, Phase 2 receives 40%, and Phase 3 receives the remainder. If Phase 3 funds are split equally among 6 research teams, how much does each team receive? - Malaeb
A science administrator is allocating $2.4 million in research grants across three phases of a gene therapy project. Phase 1 receives 25% of the total, Phase 2 receives 40%, and Phase 3 receives the remainder. If Phase 3 funds are split equally among 6 research teams, how much does each team receive?
A science administrator is allocating $2.4 million in research grants across three phases of a gene therapy project. Phase 1 receives 25% of the total, Phase 2 receives 40%, and Phase 3 receives the remainder. If Phase 3 funds are split equally among 6 research teams, how much does each team receive?
In an era where precision and strategic investment define progress, sudden discussions around large-scale research funding are emerging across scientific and funding communities. Recent reports highlight growing emphasis on structured grant distribution in emerging medical fields—particularly gene therapy, where coordinated financial planning supports innovation from early discovery to team-based research. Meanwhile, specialized administrators are managing multi-million-dollar portfolios to ensure balanced progress across project phases. The current allocation of $2.4 million reflects this strategic approach, revealing how funding decisions shape scientific outcomes.
This specific funding allocation divides the total grant into three carefully planned phases. Phase 1 captures 25%—typically dedicated to foundational research and initial testing. Phase 2, receiving the largest share at 40%, supports advanced development and milestone-driven experiments. Phase 3’s remainder funds—30% of the total—enable broader exploration and cross-disciplinary collaboration. This systematic phasing aligns with modern practices in research management, prioritizing sustainability and measurable progress.
Understanding the Context
If Phase 3 receives 30% of $2.4 million, the total amount available for the six research teams becomes clear: 30% of 2,400,000 equals $720,000. This sum funds six teams equally, ensuring every group receives proportional support. Calculation is straightforward: $720,000 ÷ 6 = $120,000 per team. This clarity supports transparency and trust—key in grant-making circles.
Why Is This Allocation Trendsetting?
The phased funding model reflects a shift toward disciplined, milestone-based resource deployment. With gene therapy increasingly central to breakthrough
